These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 29522865)

  • 1. Intradetrusor Injections of Botulinum Toxin Type A in Children With Spina Bifida: A Multicenter Study.
    Hascoet J; Peyronnet B; Forin V; Baron M; Capon G; Prudhomme T; Allenet C; Tournier S; Maurin C; Cornu JN; Bouali O; Peycelon M; Arnaud A; Renaux-Petel M; Liard A; Karsenty G; Manunta A; Game X
    Urology; 2018 Jun; 116():161-167. PubMed ID: 29522865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum injection is useless on fibrotic neuropathic bladders.
    Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
    J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradetrusor Injections of Botulinum Toxin A in Adults with Spinal Dysraphism.
    Peyronnet B; Even A; Capon G; De Seze M; Hascoet J; Biardeau X; Baron M; Perrouin-Verbe MA; Boutin JM; Saussine C; Phé V; Lenormand L; Chartier-Kastler E; Cornu JN; Karsenty G; Manunta A; Schurch B; Denys P; Amarenco G; Game X;
    J Urol; 2018 Oct; 200(4):875-880. PubMed ID: 29746860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
    Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
    J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predicting the success of intradetrusor onabotulinum toxin-A treatment in children with neurogenic bladders due to myelomeningocele: The outcomes of a large cohort.
    Danacioglu YO; Keser F; Ersoz C; Polat S; Avci AE; Kalkan S; Silay MS
    J Pediatr Urol; 2021 Aug; 17(4):520.e1-520.e7. PubMed ID: 33712371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
    Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
    J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele.
    Horst M; Weber DM; Bodmer C; Gobet R
    Neurourol Urodyn; 2011 Nov; 30(8):1546-9. PubMed ID: 21674597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review.
    Hascoet J; Manunta A; Brochard C; Arnaud A; Damphousse M; Menard H; Kerdraon J; Journel H; Bonan I; Odent S; Fremond B; Siproudhis L; Gamé X; Peyronnet B;
    Neurourol Urodyn; 2017 Mar; 36(3):557-564. PubMed ID: 27187872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Electromotive Botulinum Toxin Type "A" Administration for Management of Urinary Incontinence Secondary to Neuropathic Detrusor Overactivity in Children: Long-term Follow-up.
    Ladi-Seyedian SS; Sharifi-Rad L; Kajbafzadeh AM
    Urology; 2018 Apr; 114():167-174. PubMed ID: 29229221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.
    Alvares RA; Silva JA; Barboza AL; Monteiro RT
    Int Braz J Urol; 2010; 36(6):732-7. PubMed ID: 21176280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
    Naqvi S; Clothier J; Wright A; Garriboli M
    J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration.
    Ladi-Seyedian SS; Sharifi-Rad L; Kajbafzadeh AM
    Urology; 2020 Aug; 142():190-194. PubMed ID: 32437774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
    Ghalayini IF; Al-Ghazo MA; Elnasser ZA
    Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of toxin-A Botulinum for treating intractable bladder hyperactivity in children affected by neuropathic bladder secondary to myelomeningocele: an alternative to enterocystoplasty].
    Marte A; Vessella A; Cautiero P; Romano M; Borrelli M; Noviello C; Del Gado R; Parmeggiani P
    Minerva Pediatr; 2005 Feb; 57(1):35-40. PubMed ID: 15791200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
    Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X
    J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Marque P; Rischmann P; Gamé X
    World J Urol; 2016 May; 34(5):755-61. PubMed ID: 26282099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.